Stocks Health care VERA
NASDAQ · Health careVera Therapeutics, Inc. (VERA)
It posted a net loss of $415.3M. In fiscal 2025 capital spending exceeded operating cash flow by $241.7M. At September 30, 2026 it held $55.3M in cash against $75.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Vera Therapeutics, Inc.
- Net worth
- Vera Therapeutics, Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $333.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $241.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vera Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Vera Therapeutics, Inc. does
Vera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VERA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$299.6M | -$4.66 | -$241.7M |
| 2024 | n/a | -$152.1M | -$2.75 | -$135.7M |
| 2023 | n/a | -$96M | -$2.25 | -$92.2M |
| 2022 | n/a | -$89.1M | -$3.35 | -$67.7M |
| 2021 | n/a | -$32.6M | -$2.43 | -$23.7M |
| 2021 | n/a | -$53.4M | -$166.93 | -$34.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Vera Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue was $10.3M; diluted EPS -$1.30 versus -$1.26.
- November 5, 2026
- September 15, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 10, 2026
- July 30, 2026Passive stake changed SCHEDULE 13G/A
- July 9, 2026
- July 7, 2026Other event 8-K
- June 2, 2026Other event 8-K
Insider trades
What the people running Vera Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Fordyce MarshallPRESIDENT AND CEO, Director | Exercised options | 18,500 | $53.6K |
| September 15, 2026 | Fordyce MarshallPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 18,500 | $684.5K |
| September 11, 2026 | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | Exercised options | 5,000 | $19.7K |
| September 2, 2026 | Fordyce MarshallPRESIDENT AND CEO, Director | Exercised options | 18,500 | $53.6K |
| September 2, 2026 | Fordyce MarshallPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 18,500 | $649.6K |
| August 3, 2026 | Boman Nancy LeeChief Regulatory Officer | Received as pay | 44,987 | - |
| July 7, 2026 | Fordyce MarshallPRESIDENT AND CEO, Director | Exercised options | 46,250 | $134K |
| July 7, 2026 | Fordyce MarshallPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 1,000 | $40.8K |
Who owns VERA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 8.9% | February 14, 2025 |
| Patrick G. Enright13D, may seek influence with 5 related filers | 8.4% | November 4, 2024 |
| T. Rowe Price Associates, Inc.13G, passive | 6.4% | May 15, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 5.5% | March 11, 2026 |
| Deerfield Mgmt, L.P.13G, passive with 3 related filers | 5.25% | June 11, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 219 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,747,760 | +659,658 |
| Avoro Capital Advisors LLC | 5,723,888 | -165,000 |
| State Street Corp | 4,148,786 | +785,148 |
| Deep Track Capital, LP | 4,000,000 | -106,067 |
| Deerfield Management Company, L.P. | 3,916,400 | +194,300 |
| Kynam Capital Management, LP | 2,890,059 | -508,165 |
| Morgan Stanley | 2,799,459 | +2,430,699 |
| Sofinnova Investments, Inc. | 2,793,987 | 0 |
| Fmr LLC | 2,774,070 | +97,648 |
| Vanguard Capital Management LLC | 2,755,413 | +71,806 |
| Eversept Partners, LP | 2,212,770 | +39,484 |
| Logos Global Management LP | 2,200,000 | new |
| Integral Health Asset Management, LLC | 1,750,000 | +150,000 |
| Bellevue Group AG | 1,710,808 | +37 |
| Geode Capital Management, LLC | 1,692,442 | +122,365 |
| Alliancebernstein L.P. | 1,591,043 | +276,801 |
| Goldman Sachs Group Inc | 1,380,835 | +246,866 |
| Frontier Capital Management Co LLC | 1,295,405 | +743,912 |
| Pictet Asset Management Holding SA | 1,249,414 | +197,831 |
| Deutsche Bank AG\ | 1,102,106 | +569,640 |
Insiders
11 insiders reported holding 778,792 shares in total, about $23.8M at the last price.
| Holder | Shares |
|---|---|
| Fordyce MarshallPRESIDENT AND CEO, Director | 235,244 |
| Grant SeanCHIEF FINANCIAL OFFICER | 114,181 |
| Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | 80,754 |
| Skelton Laurence MatthewChief Commercial Officer | 64,218 |
| Brenner RobertChief Medical Officer | 50,947 |
| Carter Jason SChief Legal Officer | 49,136 |
| Johnson David LeeChief Operating Officer | 45,727 |
| Turner William D.Chief Regulatory Officer | 45,313 |
| Boman Nancy LeeChief Regulatory Officer | 44,987 |
| Wright-Mitchell JaneChief Legal Officer | 42,403 |
Questions about VERA
What does Vera Therapeutics, Inc. do?
Vera Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as VERA. Its shares trade on NASDAQ under the ticker VERA.
What is Vera Therapeutics, Inc.'s net worth?
Vera Therapeutics, Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $333.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vera Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $415.3M.
When did Vera Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Vera Therapeutics, Inc.'s next earnings report?
Vera Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VERA with
Follow VERA
Get an email when Vera Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vera Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.